H19 and chronic myelogenous leukemia, BCR-ABL1 positive: Reduced expression of H19 was observed in clinically untreated chronic myeloproliferative disorders, including chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) and chronic myelomonocytic leukemia (CMML), as well as in AML [53, 54].